ATOS logo

Atossa Therapeutics, Inc. Common Stock


ATOS: Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.


Show ATOS Financials

Consumer Interest
SEC Filings

Recent trades of ATOS by members of U.S. Congress

Recently reported changes by institutional investors

Quarterly net insider trading by ATOS's directors and management

Government lobbying spending instances

  • $40,000 Jan 20, 2016 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Oct 20, 2015 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Sep 03, 2015 Issue: Medical/Disease Research/Clinical Labs
U.S. Patents

New patents grants

  • Patent Title: Methods for making and using endoxifen Jun. 20, 2023
  • Patent Title: Methods for making and using endoxifen Feb. 07, 2023
  • Patent Title: Methods for making and using endoxifen Mar. 01, 2022
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of ATOS in WallStreetBets Daily Discussion


Recent insights relating to ATOS

CNBC Recommendations

Recent picks made for ATOS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ATOS

Corporate Flights

Flights by private jets registered to ATOS